Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Government Takes First Steps To De-link Indigenous Innovation And Procurement, But Industry Groups Wary

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Months after pledging a policy change, China is finally taking steps to break ties between indigenous innovation and government procurement policies. The changes in policy, according to a report released by the U.S.-China Business Council, address growing concern among multinationals that procurement policies - an estimated $1 trillion market - are increasingly designed to shut them out

You may also be interested in...



Rising Labor Cost Top Risk For Multinationals In China – AmCham Survey

A slowing economy and regulatory uncertainty loom large for multinationals operating in China. However, companies say rising labor costs impact them more, and acute shortages of qualified employees further complicate the landscape.

A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases

With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.

A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases

With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel